Core Viewpoint - The stock of Tongyuan Kang Pharmaceutical-B (02410) has seen a significant increase, rising nearly 7% before stabilizing at a 5.82% gain, trading at HKD 15.08 with a transaction volume of HKD 73.088 million [1] Group 1: Clinical Research Developments - The company announced early clinical research results for three cell cycle protein-dependent kinase inhibitors (CDKis): TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i), which will be presented at the 2025 ESMO Annual Meeting in Berlin from October 17 to 21 [1] - Tongyuan Kang's drug, Aditinib (TY-9591), targeting non-small cell lung cancer brain metastases, has garnered significant attention following its key Phase II clinical trial results presented at the World Lung Cancer Conference in September 2025 [1] Group 2: Regulatory Milestones - The company completed the enrollment of 224 patients for the conditional approval of Aditinib in November 2024 and submitted a Pre-NDA application in April 2025, with plans to formally submit a conditional NDA application in Q4 2025 [1]
港股异动 | 同源康医药-B(02410)午前涨近7% 公司在ESMO年会公布多项CDK抑制剂临床积极数据